Trial reportArthritis research & therapy2026
Safety, tolerability, pharmacokinetics, and pharmacodynamics of ABP-671 in healthy participants and patients with hyperuricemia and gout: a proof-of-concept study.
Trial report in Arthritis research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis proof-of-concept study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of ABP-671, a novel URAT1 inhibitor, in healthy participants and in patients with hyperuricemia and gout.
methodsThis single-center, randomized, double-blind, placebo-controlled phase I/IIa clinical trial consisted of two parts: a single ascending dose study (SAD) in healthy participants (0.5, 1, 3, and 6 mg, with two participants receiving placebo and six participants receiving ABP-671 tablets per dose cohort), and a multiple ascending dose (MAD) study in patients with hyperuricemia and gout (1, 2, 4, 6 and 12 mg daily, with two patients receiving placebo and seven patients receiving ABP-671 tablets per cohort).
resultsThirty-two and 45 Chinese participants were enrolled in the SAD and MAD studies, respectively. In the SAD and MAD studies, eight (25.0%) and 24 (53.3%) participants reported treatment-emergent adverse events (TEAEs), respectively; there were no serious AEs (SAEs), and no grade ≥ 3 TEAEs. In the MAD study, the maximum mean serum urate decrease from baseline in patients with gout was 17.7% (placebo), 56.4% (1 mg QD), 58.1% (2 mg QD), 69.4% (4 mg QD), 77.0% (6 mg QD), and 79.2% (12 mg QD), respectively. The maximum mean serum urate decrease from baseline in serum urate in patients with hyperuricemia was 19.9% (placebo), 50.1% (1 mg QD), 64.1% (2 mg QD), 73.2% (4 mg QD), 81.2% (6 mg QD), and 82.1% (12 mg QD), respectively.
conclusionsABP-671 had an acceptable safety profile in Chinese healthy participants and patients with hyperuricemia and gout. ABP-671 reduced serum urate levels in a dose-dependent manner.
trial registrationhttps://chinadrugtrials.org.cn (No. CTR20211668) .
Indexed as
Identifiers
42332828What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.